Journal: PLOS Pathogens
Article Title: Preexisting helminth challenge exacerbates infection and reactivation of gammaherpesvirus in tissue resident macrophages
doi: 10.1371/journal.ppat.1011691
Figure Lengend Snippet: (A) Timeline of intraperitoneal IL-4 complex (IL-4c), thioglycolate (Thio) treatments and MHV68.ORF73β-lactamase intraperitoneal infection (10 6 plaque forming units (PFU)). 5μg of IL-4 and 25 μg α-IL-4 were complexed and injected for LPM expansion. 3.8% sterile thioglycolate broth was used to expand SPMs. The time point shown in (B-H) is outlined by a red box. (B) Quantification of flow cytometric analysis of LPMs, SPMs, and B cells at 2 days post MHV68 infection. LPMs were gated as CD19- CD11b hi ICAM-2 hi . SPMs were gated as CD19- CD11b+ ICAM-2 lo . B cells were gated as CD19+. Data are pooled from 3 independent experiments (n = 10-12/group, mean ± standard deviation). (C) Representative flow plots of the macrophage populations with the different treatments. All mice were infected with MHV68.ORF73β-lactamase. (D-F) Mice were infected as in A with 10 6 PFU of MHV68.ORF73β-lactamase virus. Quantification of flow cytometric analysis of MHV68-infected PECs at day 2 post MHV68 infection. Data are pooled from 3 independent experiments (n = 10-12/group, mean ± standard deviation). (D) Quantification of the total number of MHV68-infected PECs. (E) Proportion of total MHV68-infected PECs for each treatment. (F) Number of MHV68-infected LPMs, SPMs, and B cells. (G) Proportion of MHV68-infected LPMs and SPMs out of the LPM and SPM populations, respectively. (H) Proportion of MHV68-infected LPMs and SPMs out of the LPM and SPM populations, respectively. 2-way ANOVA analysis compared proportion of LPMs to SPMs for each treatment. Each dot represents an individual mouse. (B, F, G, H) P-values, 2-way ANOVA, Tukey’s multiple comparisons * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001 (D, E) P-values, Ordinary 1-way ANOVA, Tukey’s multiple comparisons * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001.
Article Snippet: CD11b+ cells were stained with Fc block α-CD16/32 (Biolegend) and then PE-Cy7-α-CD19 (1D3, Tonbo), Fitc-α-CD11b (M1/70, BD Biosciences), BV510-α-F4/80 (BM8, Biolegend), BV711-α-Siglec F (E50-2440, BD Biosciences), Violetfluor 450-α-Ly-6G (GR1) (RB6-8B5, Tonbo), and Alexafluor 647-α-CD102 (3C4 (MIC2/4), Biolegend).
Techniques: Infection, Injection, Sterility, Standard Deviation, Virus